Xerava (eravacycline)
- Region
- 🇪🇺 EU
- Active substance
- eravacycline
- Company
- PAION Pharma GmbH
- Status
- Authorised
- Therapeutic area
- Infection; Bacterial Infections
- EU approval
- Thu 20 Sep 2018
- Application
- EMEA/H/C/004237
- ATC
- J01AA13
- Official record
- www.ema.europa.eu
Indication
Xerava is indicated in adolescents from the age of 12 years weighing at least 50 kg, and in adults, for the treatment of complicated intra-abdominal infections (cIAI). Consideration should be given to official guidance on the appropriate use of antibacterial agents.
Regulatory milestones
No milestones recorded in the last year.
Follow Xerava
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.